Cited by 118Heart Failure Treatment and ManagementThyroid Disorders and TreatmentsHormonal and reproductive studies

DITPA (3,5-Diiodothyropropionic Acid), a Thyroid Hormone Analog to Treat Heart Failure: Phase II Trial Veterans Affairs Cooperative Study

Goldman, Steven, McCarren, Madeline, Morkin, Eugene, Ladenson, Paul W., Edson, Robert, Warren, Stuart, Ohm, Janet, Thai, Hoang +10 more·2009·Circulation

Abstract

Background—In animal studies and a pilot trial in patients with congestive heart failure, the thyroid hormone analog 3,5 diiodothyropropionic acid (DITPA) had beneficial hemodynamic effects. Methods and Results—This was a phase II multicenter, randomized, placebo-controlled, double-blind trial of New York Heart Association class II to IV congestive heart failure patients randomized (2:1) to DITPA or placebo and treated for 6 months. The study enrolled 86 patients (n=57 to DITPA, n=29 to placebo). The primary objective was to assess the effect of DITPA on a composite congestive heart failure end point that classifies patients as improved, worsened, or unchanged based on symptom changes and morbidity/mortality. DITPA was poorly tolerated, which obscured the interpretation of congestive heart failure-specific effects. Fatigue and gastrointestinal complaints, in particular, were more frequent in the DITPA group. DITPA increased cardiac index (by 18%) and decreased systemic vascular resistance (by 11%), serum cholesterol (−20%), low-density lipoprotein cholesterol (−30%), and body weight (−11 lb). Thyroid-stimulating hormone was suppressed in patients given DITPA, which reflects its thyromimetic effect; however, no symptoms or signs of potential hypothyroidism or thyrotoxicosis were seen. Conclusions—DITPA improved some hemodynamic and metabolic parameters, but there was no evidence for symptomatic benefit in congestive heart failure.

Integrity signals

Registry

Crossref · 10.1161/circulationaha.108.834424

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Another RCT showed that the TH analogue 3,5 di-iodothyropropionic acid improved some hemodynamic variables in heart failure.

    “A small RCT [85] in patients with dilated cardiomyopathy showed beneficial effects of medium-term (3 months) levothyroxine treatment on cardiac performance, whereas another RCT [86] showed that the TH analogue 3,5 di-iodothyropropionic acid improved some hemodynamic variables in heart failure.”

    From An update on non-thyroidal illness syndrome (2021) · cites this paper as [86]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Goldman, S., McCarren, M., Morkin, E., Ladenson, P. W., Edson, R., Warren, S., Ohm, J., Thai, H., Churby, L., Barnhill, J., O'Brien, T., Anand, I., Warner, A., Hattler, B., Dunlap, M., Erikson, J., Shih, M.-C., & Lavori, P.
Affiliations
  • University of Arizona (US)
  • From Cardiology, Southern Arizona VA Health Care System (S.G., J.O., H.T.), Tucson, Ariz; VA Pharmacy Benefits Management (M.M.), Hines, Ill; University of Arizona (E.M.), Tucson, Ariz; Johns Hopkins University (P.W.L.), Baltimore, Md; R&D Service (R.E., L.C., M.-C.S., P.L.), Veterans Affairs Medical Center, Palo Alto, Calif; R&D Service (S.W., J.B.), Veterans Affairs Medical Center, Albuquerque, NM; Cardiology (T.O.), Veterans Affairs Medical Center, Charleston, SC; Cardiology (I.A.),...
Venue
Circulation
Published
2009-06-23
Volume
119
Issue
24
Pages
3093-3100
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W2146450311
Cited by
117
References
28
Citations by year
2026: 2 · 2025: 6 · 2024: 3 · 2023: 3 · 2022: 1 · 2021: 6 · 2020: 9 · 2019: 8 · 2018: 3 · 2017: 8 · 2016: 11 · 2015: 6 · 2014: 10 · 2013: 10 · 2012: 7
FWCI
6.69
Type
journal article
Language
en
Open access
closed
Locations
  • Circulation (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
Keywords
thyroid hormone analogs, congestive heart failure, cardiac index, systemic vascular resistance, serum cholesterol, TSH suppression, drug tolerability, fatigue, hypothyroidism
MeSH terms
Adolescent, Adult, Aged, Body Weight, Cholesterol, Diiodothyronines, Double-Blind Method, Fatigue, Female, Gastrointestinal Diseases, Heart Failure, Humans, Lipoproteins, LDL, Male, Middle Aged, Propionates, Thyroid Hormones, United States, United States Department of Veterans Affairs, Vascular Resistance

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review